The Enterprise Value as of December 2024 (TTM) for Regeneron Pharmaceuticals, Inc. (REGN) is 77.46B

According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 77.46B. This represents a change of -27.53% compared to the average of 106.89B of the last 4 quarters.

Regeneron Pharmaceuticals, Inc. (REGN) Historical Enterprise Value (quarterly & annually)

How has REGN Enterprise Value performed in the past?

The mean historical Enterprise Value of Regeneron Pharmaceuticals, Inc. over the last ten years is 56.64B. The current 77.46B Enterprise Value has changed 13.58% with respect to the historical average. Over the past ten years (40 quarters), REGN's Enterprise Value was at its highest in in the June 2024 quarter at 115.04B. The Enterprise Value was at its lowest in in the September 2019 quarter at 31.01B.

Regeneron Pharmaceuticals, Inc. (REGN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Regeneron Pharmaceuticals, Inc. (REGN) Average Enterprise Value

How has REGN Enterprise Value performed in the past?

The current Enterprise Value of Regeneron Pharmaceuticals, Inc. (REGN) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Regeneron Pharmaceuticals, Inc. (REGN) Enterprise Value vs. Peers

How is REGN’s Enterprise Value compared to its peers?

Regeneron Pharmaceuticals, Inc.’s Enterprise Value is greater than CRISPR Therapeutics AG (3.45B), less than Novo Nordisk A/S (2.61T), greater than Sarepta Therapeutics, Inc. (12.84B), greater than Intellia Therapeutics, Inc. (1.21B), greater than Incyte Corporation (12.16B), greater than Alnylam Pharmaceuticals, Inc. (31.44B), greater than United Therapeutics Corporation (15.10B), greater than Ultragenyx Pharmaceutical Inc. (3.88B), greater than Apellis Pharmaceuticals, Inc. (4.20B), greater than PTC Therapeutics, Inc. (3.40B), greater than Reata Pharmaceuticals, Inc. (6.64B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Krystal Biotech, Inc. (4.20B), greater than Madrigal Pharmaceuticals, Inc. (6.68B), greater than BeiGene, Ltd. (18.17B), greater than BioMarin Pharmaceutical Inc. (12.65B), greater than ImmunoGen, Inc. (8.19B), greater than Prometheus Biosciences, Inc. (9.30B), greater than Arrowhead Pharmaceuticals, Inc. (2.82B), greater than Ionis Pharmaceuticals, Inc. (6.86B),

Build a custom stock screener for Regeneron Pharmaceuticals, Inc. (REGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Regeneron Pharmaceuticals, Inc. (REGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.